Premium
A phase 1 dose‐escalation study of XmAb ® 2513 in patients with relapsed or refractory Hodgkin lymphoma
Author(s) -
Kumar Anita,
Blum Kristie A.,
Fung Henry C.,
Smith Mitchell R.,
Foster Paul A.,
Younes Anas
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13152
Subject(s) - brentuximab vedotin , medicine , antibody , monoclonal antibody , cd30 , antigen , immunology , humanized antibody , lymphoma , pharmacology , cancer research